Alterity Therapeutics Limited
Alterity Therapeutics Limited (ATHE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
athe · stock forecast · 8 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $3.92
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $3.77 | ↓ 3.94% |
1-day model range: $3.74–$3.79. Peak: $3.79 (-3.94%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -41.2% |
| 2028 | $2 | -53.3% |
| 2029 | $2 | -58.1% |
| 2030 | $2 | -60.3% |
| 2031 | — | -61.3% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ATHE · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-01-30 | Maxim Group | Maintains | Buy→Buy |
| 2024-03-07 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2023-06-05 | Ladenburg Thalmann | Maintains | Buy→Buy |
| 2022-08-03 | Ladenburg Thalmann | Maintains | Buy→Buy |
| 2022-06-23 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2021-08-20 | Benchmark | Maintains | Speculative Buy→Buy |
| 2018-01-05 | B. Riley FBR | Maintains | Buy→Buy |
| 2014-03-31 | H.C. Wainwright | Downgrade ↓ | Buy→Neutral |
| 2014-03-31 | MLV & Co. | Downgrade ↓ | Buy→Hold |
| 2014-02-26 | H.C. Wainwright | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Alterity Therapeutics Limited (ATHE) stock. Of the recent 12 rating actions, 0 were upgrades and 2 were downgrades. 8 analysts currently cover ATHE.
Analyst Recommendation Trends
ATHE analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$5M
↓ 47.6% YoY
Revenue Next Year
$3M
↓ 51.2% YoY
EPS This Year
$-0.72
EPS Next Year
$-0.89
↑ 23.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast ATHE EPS of $-0.72 for the current fiscal year, based on estimates from 1 analysts. The ATHE revenue forecast is $5M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ATHE stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ATHE price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The ATHE short-term stock prediction for tomorrow is $3.77 (-3.94%). The ATHE stock price prediction for 2027 estimates an average of $2. The ATHE stock prediction for 2030 projects a range of $1–$2.
Alterity Therapeutics Limited trades on NASDAQ under the ticker ATHE. The ATHE stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
ATHE forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month ATHE price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $3.92.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.